CTOs on the Move

Industrial Pharmaceutical Resources

www.iprinc.net

 
Industrial Pharmaceutical Resources is a Bartlett, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.iprinc.net
  • 1241 Hardt Cir
    Bartlett, IL USA 60103
  • Phone: 630.823.4700

Executives

Name Title Contact Details

Similar Companies

Bioniche Pharma USA

Bioniche Pharma USA LLC is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.

Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.